IFNB1 and pulmonary sarcoidosis: Of these three patients, one was a 39-year-old woman with skin and pulmonary involvement after 3 years of IFN-β treatment, the second one was a 35-year-old man who developed pulmonary sarcoidosis after 6 years of IFN-β treatment, and the third one was a 30-year-old woman with a 5-month history of IFN-β treatment who also had only pulmonary sarcoidosis [13-15].